US · Healthcare · Biotechnology
EPS came in at -0.59 against a street estimate of -0.10 — a miss of 490.0%.
Analysts rate Zymeworks Inc. Common Stock a strong buy (8 buy, 2 hold, 0 sell out of 10) with an average price target of $39.33.
| Fund | Stake |
|---|---|
| EcoR1 Capital, LLC | 31.22% |
| Rubric Capital Management LP | 9.51% |
| BlackRock Inc | 6.19% |
| Bvf Inc | 5.08% |
| Perceptive Advisors LLC | 4.77% |
| Morgan Stanley - Brokerage Accounts | 3.37% |
| BNP Paribas Investment Partners SA | 2.59% |
| Vanguard Capital Management, LLC | 2.32% |
| Document | Date |
|---|---|
| Material agreement · Q2 2026 | 2026-06-29 |
| Reg FD disclosure · Q2 2026 | 2026-05-14 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Board / officer change · Q1 2026 | 2026-04-01 |
| Annual report FY2025 | 2026-03-02 |
| Proxy statement · Q4 2025 | 2025-11-10 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Zymeworks Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.